Hoe gaat de overheid hiermee om? Wat zijn de overwegingen? Wanneer wordt bijv. besloten tot verkorting van de PSUR cycle.

Slides:



Advertisements
Similar presentations
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010
Decision making: managing risk Summary of an ISoP workshop, Berlin, 2004.
Safety Reporting IN Clinical Trials
Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.
© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
06/05/2015 Risk Management Plan 24. April 2008 Helge Gydesen Epidemiology Novo Nordisk A/S.
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
Slide 1 November 2008 Name Sarah Morgan © Crown copyright 2005 Pharmacovigilance Working Party - Role and future perspective Sarah Morgan Medicines and.
© Safeguarding public health Implementing Medical Device Regulation and Maintaining Patient Safety Name Nicola Lennard Date October 2011.
1 BMS Confidential – for internal purposes only Pharmacovigilance and Drug Safety Track AN INDUSTRY PERSPECTIVE Amrit Ray, MD, MBA, FCMI Vice President,
Pharmacovigilance and Risk Management Chapter 17.
Meldingen 30 november 2011 Anja van Haren EudraVigilance Coördinator Informatiebijeenkomst nieuwe wetgeving farmacovigilantie.
STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA KIOGORA MWITI GATIMBU REG NO.U51/64042/2013 M.PHARM-EPIVIGIL 24 TH.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Pharmacovigilance obligations of the Pharmaceutical companies in India
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
FDA Public Hearing: Reporting of Adverse Events to Institutional Review Boards March 21, 2005 CIOMS VI Working Group Proposals Wendy P. Stephenson, MD,
1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
Sten Olsson WHO Programme Expert Uppsala Monitoring Centre Sweden
European Enforcement of Pharmacovigilance and Inspection Trends Is compliance possible within the EU? June 7, 2007 Dr. M.C. Koster CEO Vigilex Group.
1Presentation Name Pre-Marketing Safety Assessment: The Safety Review Guidance Armando Oliva, M.D. Associate Director for Policy Office of New Drugs.
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. European.
Concept Paper #3: Risk Assessment of Observational Data Session 1: Good Pharmacovigilance Practices Linda S. Hostelley on behalf of PhRMA.
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.
Summary of Findings Improving the System of Reporting and Interpreting Unexpected Serious Adverse Events to Investigators Conducting Research Under an.
FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Minimum requirements for Pharmacovigilance in countries.
PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.
Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Periodic Safety Update Reports (PSURs)
PharmacoVigilance: Development of PhV systems and processes.
TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.
PharmacoVigilance: Development of PhV systems and processes VICH Workshop, Dar Es Salaam, Tanzania, 24 June 2015.
Medicines Act: Pharmacovigilance and the Medical Profession.
1 Division of Pharmacoepidemiology and Pharmacovigilance AEMPS Dolores Montero Corominas 20 November Management of the Adverse drug reaction (ADR),
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
Social Pharmacy and Pharmacovigilance
Principles of Risk Management
Detection & monitoring of ADR
Efficacy and Safety of Medicines
Periodic Safety Update Reports (PSUR)
Information on Medicinal Products
EudraVigilance.
Within Trial Decisions: Unblinding and Termination
Pharmacovigilance in clinical trials
9. Introduction to signal detection
TAIEX, Istanbul, April 19th, 2011
Helen Lee, European Commission
7. aDSM slides - Indicators of aDSM implementation and programme management Multi-partner training package on active TB drug safety monitoring and management.
Pharmacovigilance updates
Aspects of pharmacovigilance: Development Safety Update Report (DSUR)
Patient Involvement in the Development and Use of Safe Medicines Introductory Section – Concepts to Consider CIOMS XI WG Second Meeting October 23-24,
Presentation transcript:

Hoe gaat de overheid hiermee om? Wat zijn de overwegingen? Wanneer wordt bijv. besloten tot verkorting van de PSUR cycle

wetgeving Council regulation 2309/93 540/95 Directive 75/319 as amended

System for drug surveillance (National pharmacovigilance centre) for receipt and evaluation of all pharmacovigilance data within that Member State

The CA as part of its obligation to undertake ongoing evaluation of risk benefit assessment, must ensure that all pharmacovigilance data received and outlined are taken into account on an ongoing basis

Individual adverse reaction reports Periodic Safety Reports Company Sponsored Post Authorisation Safety Studies Pharmacovigilance data from other sources

Objective: provide an update of the world wide safety experience The regulatory authorities regard the PSURs as important summaries and analyses of drug safety data

With a focus on all serious and non serious unlisted adverse events they can prove a valuable source of drug safety signals The accumulation of all clinical safety data from all relevant sources provides an excellent opportunity to carry out an overall safety evaluation of the product

PSUR European PSURs follow the format and content for safety updates as ICH E2C requirements European authorization National authorization

Waarde van de PSUR Kwaliteit Mening registratiehouder Spontane meldingen

Waarde van de PSUR Causality assessment Underreporting Vulnerabilty to external events

overemphasis on rare ADRs

Aandachtspunten ICH E2C Cyclus Summary Bridging rapport CCDS

Instrumenten:  Aanpassen SPC  Verandering cyclus  Closely monitoring

Toekomst ICH E2E Eudravigilance database Work sharing

Surveillance Describe patterns of occurrence Identify unusual events Provide early warnings Track trends

wetgeving Volume 9 ICH E2C ICH E2E

Major issue spontaneous data Draw conclusion from inaccurate data At best provide a signal At worst eschew patients form beneficial therapies.

Fatal ADRs are between the fourth and the sixth leading cause of death

Some ADRs are understood recognized and accepted as necessary side effects to achieve desired benefit

Purpose of surveillance Describe patterns of occurrence Identify unusual events Provide early warnings Track trends

Spontaneous reports are the major source In the US 90% are submitted by the MAHs Drawbacks

Estimates are imprecise ADRs are a major public health problem